Skip to main content

Together we are beating cancer

Donate now

Immunotherapy

Showing 12 out of 205 results

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

by Harry Jenkins | News | 19 January 2022

19 January 2022

Non small cell lung cancer cells stained in pleural effusion sample.

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE). A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

by Harry Jenkins | News | 12 January 2022

12 January 2022

Melanoma cell. Credit: Dr Erik Sahai

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer. The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

by Harry Jenkins | News | 21 December 2021

21 December 2021

Lung cancer cells

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

by Harry Jenkins | News | 11 November 2021

11 November 2021

3D representation of oesophageal cancer

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

by Harry Jenkins | News | 20 October 2021

20 October 2021

  • Science & Technology
  • Health & Medicine

Innovative cancer spinouts: 3 new projects get green light

The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours. The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours.

by Cancer Research UK | News | 13 August 2021

13 August 2021

3D rendering of oesophageal cancer

The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer. The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer.

by Harry Jenkins | News | 11 August 2021

11 August 2021

Bowel cancer cells under a microscope

People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England. People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England.

by Harry Jenkins | News | 16 June 2021

16 June 2021

Lung adenocarcinoma cells
  • Science & Technology
  • Health & Medicine

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

by Harry Jenkins | Analysis | 9 June 2021

9 June 2021